{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-027867","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2024-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.959344+00:00","generated_at":"2026-05-31T20:49:47.076709+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Calidi Biotherapeutics announces 1-for-10 reverse stock split effective July 15, 2024","bullets":["Reverse stock split at a 1-for-10 ratio, effective 12:01 a.m. ET on July 15, 2024.","Stockholder approval obtained at special meeting on June 6, 2024; Board set ratio at 1:10.","No fractional shares will be issued; fractional shares rounded up to the next whole number.","Authorized shares of common stock remain unchanged at 330,000,000 shares.","Trading symbol remains CLDI; new CUSIP number for common stock is 320703309."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-027867","json":"https://secwatch.observer/filing/0001493152-24-027867.json","markdown":"https://secwatch.observer/filing/0001493152-24-027867.md","text":"https://secwatch.observer/filing/0001493152-24-027867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224027867/0001493152-24-027867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000149315224027867/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:49:47.076709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}